Circadian optimisation of irinotecan and oxaliplatin efficacy in mice with Glasgow osteosarcoma

T. G. Granda, R. M. D'Attino, E. Filipski, P. Vrignaud, C. Garufi, E. Terzoli, M. C. Bissery, F. Lévi

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

The relevance of circadian rhythms in irinotecan and oxaliplatin tolerability was investigated with regard to antitumour activity. Mice bearing Glasgow osteosarcoma (GOS) received single agent irinotecan (50 or 60 mg kg-1 per day) or oxaliplatin (4 or 5.25 mg kg-1 per day) at one of six dosing times expressed in hours after light onset (3, 7, 11, 15, 19 or 23 hours after light onset). Irinotecan (50 mg kg-1 per day) and oxaliplatin (4 or 5.25 mg kg-1 per day) were given 1 min apart at 7 or 15 hours after light onset, or at their respective times of best tolerability (7 hours after light onset for irinotecan and 15 hours after light onset for oxaliplatin) or worst tolerability (15 hours after light onset for irinotecan and 7 hours after light onset for oxaliplatin). Tumour growth rate was nearly halved and per cent increase in estimated life span (% ILS) was - doubled in the mice receiving irinotecan at 7 hours after light onset as compared to 15 hours after light onset (P

Original languageEnglish
Pages (from-to)999-1005
Number of pages7
JournalBritish Journal of Cancer
Volume86
Issue number6
DOIs
Publication statusPublished - Mar 18 2002

Fingerprint

oxaliplatin
irinotecan
Osteosarcoma
Light

Keywords

  • Circadian
  • Glasgow osteosarcoma
  • Irinotecan
  • Oxaliplatin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Granda, T. G., D'Attino, R. M., Filipski, E., Vrignaud, P., Garufi, C., Terzoli, E., ... Lévi, F. (2002). Circadian optimisation of irinotecan and oxaliplatin efficacy in mice with Glasgow osteosarcoma. British Journal of Cancer, 86(6), 999-1005. https://doi.org/10.1038/sj.bjc.6600168

Circadian optimisation of irinotecan and oxaliplatin efficacy in mice with Glasgow osteosarcoma. / Granda, T. G.; D'Attino, R. M.; Filipski, E.; Vrignaud, P.; Garufi, C.; Terzoli, E.; Bissery, M. C.; Lévi, F.

In: British Journal of Cancer, Vol. 86, No. 6, 18.03.2002, p. 999-1005.

Research output: Contribution to journalArticle

Granda, TG, D'Attino, RM, Filipski, E, Vrignaud, P, Garufi, C, Terzoli, E, Bissery, MC & Lévi, F 2002, 'Circadian optimisation of irinotecan and oxaliplatin efficacy in mice with Glasgow osteosarcoma', British Journal of Cancer, vol. 86, no. 6, pp. 999-1005. https://doi.org/10.1038/sj.bjc.6600168
Granda TG, D'Attino RM, Filipski E, Vrignaud P, Garufi C, Terzoli E et al. Circadian optimisation of irinotecan and oxaliplatin efficacy in mice with Glasgow osteosarcoma. British Journal of Cancer. 2002 Mar 18;86(6):999-1005. https://doi.org/10.1038/sj.bjc.6600168
Granda, T. G. ; D'Attino, R. M. ; Filipski, E. ; Vrignaud, P. ; Garufi, C. ; Terzoli, E. ; Bissery, M. C. ; Lévi, F. / Circadian optimisation of irinotecan and oxaliplatin efficacy in mice with Glasgow osteosarcoma. In: British Journal of Cancer. 2002 ; Vol. 86, No. 6. pp. 999-1005.
@article{8e6c4f1a631d44c19c605eeafcf35566,
title = "Circadian optimisation of irinotecan and oxaliplatin efficacy in mice with Glasgow osteosarcoma",
abstract = "The relevance of circadian rhythms in irinotecan and oxaliplatin tolerability was investigated with regard to antitumour activity. Mice bearing Glasgow osteosarcoma (GOS) received single agent irinotecan (50 or 60 mg kg-1 per day) or oxaliplatin (4 or 5.25 mg kg-1 per day) at one of six dosing times expressed in hours after light onset (3, 7, 11, 15, 19 or 23 hours after light onset). Irinotecan (50 mg kg-1 per day) and oxaliplatin (4 or 5.25 mg kg-1 per day) were given 1 min apart at 7 or 15 hours after light onset, or at their respective times of best tolerability (7 hours after light onset for irinotecan and 15 hours after light onset for oxaliplatin) or worst tolerability (15 hours after light onset for irinotecan and 7 hours after light onset for oxaliplatin). Tumour growth rate was nearly halved and per cent increase in estimated life span ({\%} ILS) was - doubled in the mice receiving irinotecan at 7 hours after light onset as compared to 15 hours after light onset (P",
keywords = "Circadian, Glasgow osteosarcoma, Irinotecan, Oxaliplatin",
author = "Granda, {T. G.} and D'Attino, {R. M.} and E. Filipski and P. Vrignaud and C. Garufi and E. Terzoli and Bissery, {M. C.} and F. L{\'e}vi",
year = "2002",
month = "3",
day = "18",
doi = "10.1038/sj.bjc.6600168",
language = "English",
volume = "86",
pages = "999--1005",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Circadian optimisation of irinotecan and oxaliplatin efficacy in mice with Glasgow osteosarcoma

AU - Granda, T. G.

AU - D'Attino, R. M.

AU - Filipski, E.

AU - Vrignaud, P.

AU - Garufi, C.

AU - Terzoli, E.

AU - Bissery, M. C.

AU - Lévi, F.

PY - 2002/3/18

Y1 - 2002/3/18

N2 - The relevance of circadian rhythms in irinotecan and oxaliplatin tolerability was investigated with regard to antitumour activity. Mice bearing Glasgow osteosarcoma (GOS) received single agent irinotecan (50 or 60 mg kg-1 per day) or oxaliplatin (4 or 5.25 mg kg-1 per day) at one of six dosing times expressed in hours after light onset (3, 7, 11, 15, 19 or 23 hours after light onset). Irinotecan (50 mg kg-1 per day) and oxaliplatin (4 or 5.25 mg kg-1 per day) were given 1 min apart at 7 or 15 hours after light onset, or at their respective times of best tolerability (7 hours after light onset for irinotecan and 15 hours after light onset for oxaliplatin) or worst tolerability (15 hours after light onset for irinotecan and 7 hours after light onset for oxaliplatin). Tumour growth rate was nearly halved and per cent increase in estimated life span (% ILS) was - doubled in the mice receiving irinotecan at 7 hours after light onset as compared to 15 hours after light onset (P

AB - The relevance of circadian rhythms in irinotecan and oxaliplatin tolerability was investigated with regard to antitumour activity. Mice bearing Glasgow osteosarcoma (GOS) received single agent irinotecan (50 or 60 mg kg-1 per day) or oxaliplatin (4 or 5.25 mg kg-1 per day) at one of six dosing times expressed in hours after light onset (3, 7, 11, 15, 19 or 23 hours after light onset). Irinotecan (50 mg kg-1 per day) and oxaliplatin (4 or 5.25 mg kg-1 per day) were given 1 min apart at 7 or 15 hours after light onset, or at their respective times of best tolerability (7 hours after light onset for irinotecan and 15 hours after light onset for oxaliplatin) or worst tolerability (15 hours after light onset for irinotecan and 7 hours after light onset for oxaliplatin). Tumour growth rate was nearly halved and per cent increase in estimated life span (% ILS) was - doubled in the mice receiving irinotecan at 7 hours after light onset as compared to 15 hours after light onset (P

KW - Circadian

KW - Glasgow osteosarcoma

KW - Irinotecan

KW - Oxaliplatin

UR - http://www.scopus.com/inward/record.url?scp=0037128686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037128686&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6600168

DO - 10.1038/sj.bjc.6600168

M3 - Article

VL - 86

SP - 999

EP - 1005

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 6

ER -